The efficacy and safety of alpelisib in combination with fulvestrant or letrozole in advanced HR+/HER- BC patients harboring PIK3CA mutations who progressed on or after CDK4/6i and ET therapy was then evaluated in the phase II trial BYLieve (NCT03056755). The gene discussed is PIK3CA; the disease is breast cancer.